Research programme: progressive multifocal leukoencephalopathy therapies - Alnylam Pharmaceuticals/Biogen

Drug Profile

Research programme: progressive multifocal leukoencephalopathy therapies - Alnylam Pharmaceuticals/Biogen

Alternative Names: JC virus RNAi therapeutics - Alnylam Pharmaceuticals/Biogen; PML RNAi therapeutics - Alnylam Pharmaceuticals/Biogen

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alnylam Pharmaceuticals; Biogen Idec
  • Developer Alnylam Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Progressive multifocal leukoencephalopathy

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Progressive multifocal leukoencephalopathy in USA
  • 01 Apr 2008 Pharmacodynamics data from a preclinical study in Progressive multifocal leukoencephalopathy released by Alnylam
  • 07 Nov 2007 Pharmacodynamics data from a preclinical study in progressive multifocal leukencephalopathy presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top